Adenosine receptors and cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• G-protein-coupled cell surface adenosine receptors (ARs), including A(1)AR, A(2A)AR, A(2B)AR, and A(3)AR, are upregulated in various tumor cells.
• ARs modulate tumor growth through diverse signaling pathways, presenting potential therapeutic targets.

Purpose of the Study:

• To investigate the role of different adenosine receptor subtypes in cancer development and progression.
• To explore the therapeutic potential of targeting ARs for cancer treatment.

Main Methods:

• Analysis of AR expression in tumor cells and tissues.
• Investigating the effects of AR agonists and antagonists on tumor growth and immune responses.
• Examining the involvement of signaling pathways such as Wnt, NF-kappaB, and MAP kinase.

Main Results:

• A(1)AR activation inhibits glioblastoma development via microglial cells.
• A(2A)AR activation suppresses anti-tumor immune responses, suggesting antagonists may enhance immunotherapy.
• A(2B)AR has dual roles, promoting tumor development via angiogenesis but inhibiting cell growth signals.
• A(3)AR is highly expressed in tumors, correlated with disease severity, and its agonists inhibit tumor growth by modulating Wnt and NF-kappaB pathways.

Conclusions:

• Adenosine receptors play complex roles in cancer, with distinct functions for each subtype.
• Targeting A(3)AR with specific agonists demonstrates significant potential for inhibiting tumor growth and represents a promising therapeutic strategy in cancer therapy.